Skip to content

Clinical study of neural stem cells to treat Cerebral infarction

Clinical study of neural stem cells to treat Cerebral infarction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17014173
Enrollment
Unknown
Registered
2017-12-27
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral infarction

Interventions

five:neural stem cells

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 80 years male and female; 2. All the subjects by diagnosis of cerebral infraction by head CT or MRI, and 1 minute = NIHSS=25 points; 3. The normal bone marrow hematopoietic function, no bleeding tendency, blood routine examination: HGB=90 g/L, the WBC > 4.0*10^9/L (NEU acuity 1.5*10^9/L), PLT=100*10^9/L; 4. Liver function: the total bilirubin acuities=1.5 times the upper limit of normal value; AST and ALT acuities=2.5 times the upper limit of normal value; Alkaline phosphatase acuities=1.5 times the upper limit of normal value; 5. Renal function: BUN and Cr acuities=1.5 times the upper limit of normal, creatinine clearance=80 ml/min. 6. Chest CT without evidence of acute inflammation; 7. No other serious heart, liver, kidney disease, etc; 8. No serious virus or bacteria infections; 9. The patient or legal representatives agreed to participate in this study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Highly allergic constitution or a history of severe allergic; 2. Having a mental or psychological disease can't cooperate with treatment and curative effect evaluation; 3. The systemic infection or local serious infections of patients should be anti-infection treatment; 4. The dysfunction of important organs such as heart, lungs, brain, kidney, liver et al; 5. The dysfunction of blood coagulation such as hemophilia; 6. Infectious diseases such as HIV, RPR, active tuberculosis, et al; 7. Patients with severe autoimmune diseases; 8. Other reasons not included in the healer; 9. 3 months prior to included other drug clinical research; 10. Unable or unwilling to provide informed consent or unable to comply with the requirement.

Design outcomes

Primary

MeasureTime frame
NIHSS;

Countries

China

Contacts

Public ContactXutie

The Affiliated Hospital of Xuzhou Medical University

xutie889@163.com+86 18052268399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026